Eli Lilly and Company (NYSE:LLY) Shares Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 31.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,438 shares of the company's stock after purchasing an additional 14,876 shares during the quarter. Impax Asset Management Group plc's holdings in Eli Lilly and Company were worth $50,742,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in LLY. WestEnd Advisors LLC raised its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares in the last quarter. Citizens National Bank Trust Department raised its stake in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $43,000. Prudent Man Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $48,000. Finally, O Brien Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LLY. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. Guggenheim reiterated a "buy" rating and issued a $936.00 price target on shares of Eli Lilly and Company in a report on Friday, June 20th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Wall Street Zen cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday, June 28th. Finally, HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $1,011.61.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $1.98 during trading hours on Tuesday, reaching $774.85. The company had a trading volume of 1,886,417 shares, compared to its average volume of 3,824,117. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market cap of $734.35 billion, a PE ratio of 63.05, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. The business's 50 day moving average price is $771.52 and its 200-day moving average price is $800.30. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.58 earnings per share. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.